A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)

Titre officiel

A Phase 1b Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone or Apalutamide in mCRPC (ARES: Androgen Receptor Eradication Study)

Sommaire:

The purpose of this study is to determine safety, including dose limiting toxicities, and the recommended phase 2 dose (RP2D) of EPI-7386 in separate combinations with (a) abiraterone acetate plus prednisone or prednisolone (AAP) and (b) apalutamide (dose-finding) and to determine the antitumour activity of EPI-7386 in separate combinations with (a) AAP and (b) apalutamide (dose-expansion).

Description de l'essai

Primary Outcome:

  • Number of Participants with Adverse Events (AEs)
  • Number of Participants with AEs by Severity
  • Number of Participants with Dose-limiting Toxicities (DLT)
  • Composite Response Rate
Secondary Outcome:
  • Maximum Observed Serum Concentration (Cmax) of EPI-7386 and Abiraterone
  • Time to Reach Maximum Observed Serum Concentration (Tmax) of EPI-7386 and Abiraterone
  • Area Under the Curve From Time Zero to tau (AUC[0-tau]) of EPI-7386 and Abiraterone
  • Minimum Observed Serum Concentration (Cmin) of EPI-7386 and Abiraterone
  • Observed Accumulation Index Based on Cmax (ARCmax) of EPI-7386 and Abiraterone
  • Accumulation Ratio for AUCtau (AR AUCtau) of EPI-7386 and Abiraterone
  • Maximum Observed Serum Concentration (Cmax) of EPI-7386 and Apalutamide
  • Time to Reach Maximum Observed Serum Concentration (Tmax) of EPI-7386 and apalutamide
  • Area Under the Curve From Time Zero to tau (AUC[0-tau]) of EPI-7386 and Apalutamide
  • Minimum Observed Serum Concentration (Cmin) of EPI-7386 and Apalutamide
  • Observed Accumulation Index Based on Cmax (ARCmax) of EPI-7386 and Apalutamide
  • Accumulation Ratio for AUCtau (AR AUCtau) of EPI-7386 and Apalutamide
  • Serum Prostate-Specific Antigen (PSA)

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer